In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
The replacement of the in vivo potency test (NIH test) for rabies vaccine evaluation by in vitro methods is at present discussed in many reports and also by WHO expert working groups. For this purpose, in vitro glycoprotein titration has been proposed. Among the different glycoprotein assays, we have studied two ELISA methods (immunocapture and direct plate coating with the antigen to be tested) using neutralizing mono- and polyclonal antibodies. In our view, the immunocapture method based on the use of a neutralizing monoclonal anti-glycoprotein antibody seems to be a convenient tool for the determination of the in vitro potency of rabies vaccine and of the products corresponding to the different steps of their production process.
Perrin
P
P
Rabies Unit, Institut Pasteur, Paris, France.
Morgeaux
S
S
Sureau
P
P
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral / Q000032:analysis; D002213:Capsid / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005069:Evaluation Studies as Topic; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology; D009500:Neutralization Tests; D011819:Rabies Vaccines / Q000032:analysis* / Q000302:isolation & purification / Q000592:standards; D011820:Rabies virus / Q000276:immunology; D014758:Viral Core Proteins / Q000032:analysis; D014764:Viral Proteins / Q000032:analysis / Q000276:immunology
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D006023:Glycoproteins; D011819:Rabies Vaccines; D014758:Viral Core Proteins; D014764:Viral Proteins